Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01326364 · ClinicalTrials.gov registry record
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 6
- Enrollment target
NCT01326364: Clinical Trial study, sponsored by Stanford University.
NCT01326364 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01326364 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline perfusion characteristics in those patients with resectable pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel density and vascular endothelial growth factor (VEGF) expression.
Interventions
- DRUG Iohexol
- DRUG Iodixanol
- PROCEDURE Stereotactic body radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01326364
The ClinicalTrials.gov registry entry for NCT01326364 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Iohexol is the first listed.
NCT01326364 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01326364 about?
NCT01326364 is a clinical study titled "Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection". The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to determine whether baseline...
What is the current status of trial NCT01326364?
This trial is currently terminated. The enrollment target is 6 participants. The study started on 2010-03. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01326364?
The interventions under investigation include: Iohexol (DRUG), Iodixanol (DRUG), Stereotactic body radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT01326364?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.